P3 Health Partners (PIII) Cash & Equivalents (2019 - 2026)

P3 Health Partners (PIII) has 6 years of Cash & Equivalents data on file, last reported at $25.0 million in Q4 2025.

• Quarterly Cash & Equivalents fell 35.57% year-over-year to $25.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.0 million (down 35.57% YoY) and the FY2025 annual result came in at $25.0 million, down 35.57% from the prior year.
• Cash & Equivalents slipped to $25.0 million in Q4 2025, from $37.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $110.3 million in Q1 2022 to a low of $4.3 million in Q3 2021.
• A 5-year average of $38.7 million and a median of $37.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 692.27% — and 2023, when it sank 93.49%.
• Tracing PIII's Cash & Equivalents over 5 years: stood at $5.3 million in 2021, then surged by 230.13% to $17.5 million in 2022, then soared by 107.43% to $36.3 million in 2023, then increased by 6.89% to $38.8 million in 2024, then slumped by 35.57% to $25.0 million in 2025.
• The last three Cash & Equivalents figures came in at $25.0 million (Q4 2025), $37.7 million (Q3 2025), and $38.6 million (Q2 2025), per Business Quant data.